MX353037B - Un citomegalovirus de replicacion condicionada como vacuna contral el citomegalovirus. - Google Patents
Un citomegalovirus de replicacion condicionada como vacuna contral el citomegalovirus.Info
- Publication number
- MX353037B MX353037B MX2014002815A MX2014002815A MX353037B MX 353037 B MX353037 B MX 353037B MX 2014002815 A MX2014002815 A MX 2014002815A MX 2014002815 A MX2014002815 A MX 2014002815A MX 353037 B MX353037 B MX 353037B
- Authority
- MX
- Mexico
- Prior art keywords
- cmv
- present
- infection
- vaccine
- replication defective
- Prior art date
Links
- 241000701022 Cytomegalovirus Species 0.000 title abstract 8
- 230000003362 replicative effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 230000002950 deficient Effects 0.000 abstract 3
- 230000010076 replication Effects 0.000 abstract 3
- 206010011831 Cytomegalovirus infection Diseases 0.000 abstract 1
- 206010042566 Superinfection Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007420 reactivation Effects 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a métodos para inducir una respuesta inmunitaria frente a citomegalovirus (CMV) usando un CMV modificado genéticamente que es de replicación defectuosa condicionada; los métodos de la invención pueden usarse para tratar y/o prevenir una infección primaria por CMV, una infección debida a la reactivación de un CMV latente y a una sobreinfección de una cepa diferente de CMV a la que se había encontrado previamente; la presente invención también se refiere a un CMV de replicación defectuosa que ha sido alterado recombinantemente para permitir el control externo de la replicación vírica;. las composiciones que comprenden el CMV de replicación defectuosa también están englobadas por la presente invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161532667P | 2011-09-09 | 2011-09-09 | |
PCT/US2012/053599 WO2013036465A2 (en) | 2011-09-09 | 2012-09-04 | A conditional replicating cytomegalovirus as a vaccine for cmv |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014002815A MX2014002815A (es) | 2014-04-10 |
MX353037B true MX353037B (es) | 2017-12-18 |
Family
ID=47832753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014002815A MX353037B (es) | 2011-09-09 | 2012-09-04 | Un citomegalovirus de replicacion condicionada como vacuna contral el citomegalovirus. |
Country Status (33)
Country | Link |
---|---|
US (1) | US9546355B2 (es) |
EP (3) | EP2753364B1 (es) |
JP (1) | JP5926804B2 (es) |
KR (1) | KR101668163B1 (es) |
CN (1) | CN103889462B (es) |
AR (1) | AR087772A1 (es) |
AU (1) | AU2012304783B2 (es) |
BR (1) | BR112014005404A8 (es) |
CA (1) | CA2846870C (es) |
CL (1) | CL2014000541A1 (es) |
CY (2) | CY1119107T1 (es) |
DK (2) | DK2753364T3 (es) |
ES (2) | ES2737852T3 (es) |
HR (2) | HRP20171120T1 (es) |
HU (2) | HUE045115T2 (es) |
IL (1) | IL231272B (es) |
IN (1) | IN2014CN01809A (es) |
LT (2) | LT2753364T (es) |
ME (2) | ME03488B (es) |
MX (1) | MX353037B (es) |
NZ (1) | NZ622156A (es) |
PE (1) | PE20141525A1 (es) |
PL (2) | PL3251700T3 (es) |
PT (2) | PT2753364T (es) |
RS (2) | RS56261B1 (es) |
RU (2) | RU2611198C2 (es) |
SG (1) | SG11201400419YA (es) |
SI (2) | SI3251700T1 (es) |
TR (1) | TR201910644T4 (es) |
TW (1) | TWI570240B (es) |
UA (1) | UA114896C2 (es) |
WO (1) | WO2013036465A2 (es) |
ZA (1) | ZA201401708B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150307850A1 (en) * | 2012-12-04 | 2015-10-29 | Merck Sharp & Dohme Corp. | Conditional replicating viral vectors |
BR112015030892A2 (pt) | 2013-06-10 | 2017-08-29 | Merck Sharp & Dohme | Proteína de ligação ao antígeno, anticorpo monoclonal, ácido nucleico recombinante, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma proteína de ligação ao antígeno ou anticorpo humanizado, e, método para produzir uma proteína de ligação ao antígeno |
AU2015289560B2 (en) | 2014-07-16 | 2018-09-27 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
EP3048114A1 (en) * | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
MX2020004434A (es) * | 2017-11-01 | 2020-08-06 | Merck Sharp & Dohme | Formulaciones estables de citomegalovirus. |
US20210047626A1 (en) | 2018-04-24 | 2021-02-18 | Merck Sharp & Dohme Corp. | Scalable chromatography process for purification of human cytomegalovirus |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US20220090005A1 (en) | 2019-01-03 | 2022-03-24 | Merck Sharp & Dohme Corp. | Supplemented Serum-Containing Culture Medium for Enhanced Arpe-19 Growth and Human Cytomegalovirus Vaccine Production |
EP3997107A1 (en) * | 2019-07-12 | 2022-05-18 | Københavns Universitet | Fusion toxin proteins for treatment of diseases related to cmv infections |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CN112481222B (zh) * | 2020-11-30 | 2024-01-02 | 中国医学科学院医学生物学研究所 | 一种条件复制型重组单纯疱疹病毒、疫苗及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4841726B2 (ja) * | 1999-02-05 | 2011-12-21 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒトパピローマウイルスワクチン製剤 |
EP1587816B1 (en) | 2002-12-23 | 2010-06-16 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US20060110406A1 (en) * | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
US20040228842A1 (en) * | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
MX291624B (es) * | 2005-02-18 | 2011-11-04 | Novartis Vaccines & Diagnostic | Inmunogenos de escherichia coli uropatogenica. |
EP3031469B1 (en) * | 2006-06-07 | 2023-08-23 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
US9439960B2 (en) | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
US8530636B2 (en) | 2008-05-07 | 2013-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells in vivo using synthetic small molecules |
-
2012
- 2012-09-03 TW TW101132064A patent/TWI570240B/zh active
- 2012-09-04 SI SI201231634T patent/SI3251700T1/sl unknown
- 2012-09-04 AR ARP120103253A patent/AR087772A1/es active IP Right Grant
- 2012-09-04 US US14/343,637 patent/US9546355B2/en active Active
- 2012-09-04 PL PL17171651T patent/PL3251700T3/pl unknown
- 2012-09-04 EP EP12830346.8A patent/EP2753364B1/en active Active
- 2012-09-04 CA CA2846870A patent/CA2846870C/en active Active
- 2012-09-04 PT PT128303468T patent/PT2753364T/pt unknown
- 2012-09-04 HU HUE17171651A patent/HUE045115T2/hu unknown
- 2012-09-04 NZ NZ622156A patent/NZ622156A/en unknown
- 2012-09-04 UA UAA201403638A patent/UA114896C2/uk unknown
- 2012-09-04 DK DK12830346.8T patent/DK2753364T3/en active
- 2012-09-04 PL PL12830346T patent/PL2753364T3/pl unknown
- 2012-09-04 LT LTEP12830346.8T patent/LT2753364T/lt unknown
- 2012-09-04 AU AU2012304783A patent/AU2012304783B2/en active Active
- 2012-09-04 BR BR112014005404A patent/BR112014005404A8/pt not_active Application Discontinuation
- 2012-09-04 TR TR2019/10644T patent/TR201910644T4/tr unknown
- 2012-09-04 PE PE2014000323A patent/PE20141525A1/es active IP Right Grant
- 2012-09-04 KR KR1020147008959A patent/KR101668163B1/ko active IP Right Grant
- 2012-09-04 DK DK17171651.7T patent/DK3251700T3/da active
- 2012-09-04 RU RU2014113921A patent/RU2611198C2/ru active
- 2012-09-04 EP EP19175776.4A patent/EP3572096A1/en active Pending
- 2012-09-04 IN IN1809CHN2014 patent/IN2014CN01809A/en unknown
- 2012-09-04 JP JP2014529788A patent/JP5926804B2/ja active Active
- 2012-09-04 EP EP17171651.7A patent/EP3251700B1/en active Active
- 2012-09-04 WO PCT/US2012/053599 patent/WO2013036465A2/en active Application Filing
- 2012-09-04 ES ES17171651T patent/ES2737852T3/es active Active
- 2012-09-04 ME MEP-2019-176A patent/ME03488B/me unknown
- 2012-09-04 SG SG11201400419YA patent/SG11201400419YA/en unknown
- 2012-09-04 SI SI201231003T patent/SI2753364T1/sl unknown
- 2012-09-04 RU RU2017102888A patent/RU2670012C1/ru active
- 2012-09-04 CN CN201280053360.7A patent/CN103889462B/zh active Active
- 2012-09-04 RS RS20170715A patent/RS56261B1/sr unknown
- 2012-09-04 MX MX2014002815A patent/MX353037B/es active IP Right Grant
- 2012-09-04 RS RS20190753A patent/RS58891B1/sr unknown
- 2012-09-04 HU HUE12830346A patent/HUE035322T2/en unknown
- 2012-09-04 ES ES12830346.8T patent/ES2633190T3/es active Active
- 2012-09-04 PT PT17171651T patent/PT3251700T/pt unknown
- 2012-09-04 LT LTEP17171651.7T patent/LT3251700T/lt unknown
- 2012-09-04 ME MEP-2017-157A patent/ME02831B/me unknown
-
2014
- 2014-03-02 IL IL231272A patent/IL231272B/en active IP Right Grant
- 2014-03-06 CL CL2014000541A patent/CL2014000541A1/es unknown
- 2014-03-07 ZA ZA2014/01708A patent/ZA201401708B/en unknown
-
2017
- 2017-07-20 HR HRP20171120TT patent/HRP20171120T1/hr unknown
- 2017-07-20 CY CY20171100780T patent/CY1119107T1/el unknown
-
2019
- 2019-06-18 HR HRP20191111TT patent/HRP20191111T1/hr unknown
- 2019-08-06 CY CY20191100836T patent/CY1121863T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX353037B (es) | Un citomegalovirus de replicacion condicionada como vacuna contral el citomegalovirus. | |
MX2018008413A (es) | Virus oncolitico modificado. | |
PH12017500727A1 (en) | Modified virus-like particles of cmv | |
EP3234136A4 (en) | Compositions of and methods for in vitro viral genome engineering | |
PH12016502220A1 (en) | Means and methods for treating cmv | |
MA39717A (fr) | Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs | |
PL2658570T3 (pl) | Sposoby i kompozycje szczepionki przeciwko wirusowi wirusowej biegunki bydła typu 1b | |
PH12018501750A1 (en) | Porcine reproductive and respiratory syndrome vaccine virus | |
PH12017500419B1 (en) | Recoded arbovirus and vaccines | |
EP3908315A4 (en) | COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSE TO VACCINATION AND ENHANCING VACCINE PRODUCTION | |
EP3324963A4 (en) | METHODS AND COMPOSITIONS FOR ENHANCING AN IMMUNE RESPONSE TO VACCINATION | |
IL284135A (en) | Virus-like particles of CMV modified by fusion | |
MX358507B (es) | Antigenos vacunales quimericos contra el virus de la hepatitis c. | |
MX2017014666A (es) | Metodos de inmunización contra clostridium difficile. | |
CA3045626A1 (en) | Bovine herpesvirus type 1 (bohv-1) vector against bovine respiratory disease complex | |
ECSP14013300A (es) | Un citomegalovirus de replicacion condicionada como vacuna contra el cmv | |
EP3200821A4 (en) | Therapeutic compositions and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2) | |
WO2011130652A3 (en) | Compositions and methods for vaccinating humans and animals against enveloped viruses | |
MX337048B (es) | Vacuna marcadora para la fiebre porcina clasica. | |
MX2020013284A (es) | Vacuna basada en particulas virales. | |
EP3244922A4 (en) | Methods of inducing an immune response to hepatitis c virus | |
WO2017011620A9 (en) | Methods and compositions related to increasing the fidelity of influenza a virus for vaccine development | |
MX2021015236A (es) | Métodos para el tratamiento contra infecciones virales. | |
EP3939991A4 (en) | NOVEL RECOMBINANT INFLUENZA VIRUS EDUCATING IMMUNE AND THERAPEUTIC RESPONSES AGAINST HETEROLOGOUS INFLUENZA VIRUS, AND GENETIC VACCINE AND THERAPEUTIC VACCINE COMPRISING THEM | |
GB201803787D0 (en) | Oncolytic viruses as adjuvants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |